[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647843":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":22,"responsibleParty":87,"collaborators":10,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":91,"sex":96,"minAge":97,"maxAge":10,"enrollmentInfo":98,"targetDuration":10,"studyType":101,"phases":10,"briefSummary":102,"conditions":103,"keywords":10,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"University Hospital, Bordeaux","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Emphysema secondary to alpha-1-anti-trypsin deficiency (AATD)",null,"The subjects included will be any patients followed and diagnosed between 2010 and 2025 in the pulmonology department for emphysema and COPD secondary to alpha-1 antitrypsin deficiency ZZ, Znull, ZMalton, Z and rare mutations, based on the diagnosis of emphysema made from an initial thoracic CT scan (+\u002F- 12 months after diagnosis).",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Maéva ZYSMAN, MD, PhD","CONTACT","+335 57 65 63 38","maeva.zysma@chu-bordeaux.fr",{"name":19,"role":15,"phone":20,"phoneExt":10,"email":21},"Margot GENAUD","+335 25 35 21 94","margot.genaud@chu-bordeaux.fr",[23,43,58,73],{"facility":24,"status":25,"city":26,"state":10,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Hospices Civils de Lyon","RECRUITING","Bron","69677","France","FR",{"type":31,"coordinates":32},"Point",[33,34],4.91303,45.73865,{"lat":34,"lon":33},[37,41],{"name":38,"role":15,"phone":39,"phoneExt":10,"email":40},"Jean-Francois MORNEX, MD, PhD","+334 72 11 80 17","jean-francois.mornex@univ-lyon1.fr",{"name":38,"role":42,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":44,"status":25,"city":45,"state":10,"zip":46,"country":28,"countryCode":29,"cosmosGeoPoint":47,"geoPoint":51,"contacts":52},"CHU de Lille","Lille","59000",{"type":31,"coordinates":48},[49,50],3.05512,50.63391,{"lat":50,"lon":49},[53,57],{"name":54,"role":15,"phone":55,"phoneExt":10,"email":56},"Olivier LE ROUZIC, MD, PhD","+333 20 16 05 30","Olivier.LEROUZIC@chu-lille.fr",{"name":54,"role":42,"phone":10,"phoneExt":10,"email":10},{"facility":59,"status":25,"city":60,"state":10,"zip":61,"country":28,"countryCode":29,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Hôpital BICHAT CLAUDE-BERNARD","Paris","75018",{"type":31,"coordinates":63},[64,65],2.3488,48.85341,{"lat":65,"lon":64},[68,72],{"name":69,"role":15,"phone":70,"phoneExt":10,"email":71},"Vincent BUNEL GOURDY, MD","+331 40 25 61 01","vincent.bunel@aphp.fr",{"name":69,"role":42,"phone":10,"phoneExt":10,"email":10},{"facility":74,"status":25,"city":75,"state":10,"zip":76,"country":28,"countryCode":29,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Bordeaux University Hospital","Pessac","33600",{"type":31,"coordinates":78},[79,80],-0.6324,44.80565,{"lat":80,"lon":79},[83,84,85],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},{"name":19,"role":15,"phone":20,"phoneExt":10,"email":21},{"name":86,"role":42,"phone":10,"phoneExt":10,"email":10},"Maéva ZYSMAN, MD,PhD",{"type":88,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100647843","development-of-a-prediction-score-for-the-occurrence-of-death-or-lung-transplantation-in-patients-with-emphysema-secondary-to-alpha-1-anti-tripsin-deficiency-100647843",false,"NCT07715617","Development of a Prediction Score for the Occurrence of Death or Lung Transplantation in Patients With Emphysema Secondary to Alpha-1-anti-tripsin Deficiency","FLARE","1. Inclusion criteria:\n\n   * diagnosed between 2010 and 2025\n   * in the pulmonology department\n   * diagnosis of emphysema and COPD secondary to alpha-1 antitrypsin deficiency ZZ, Znull, ZMalton, Z and rare mutations,\n   * emphysema according to the initial thoracic CT scan (+\u002F- 12 months after diagnosis).\n2. Exclusion criteria:\n\n   * Age \\\u003C18 years\n   * Patient opposed to the use of their data for research purposes\n   * Patient deprived of liberty by judicial decision\n   * Patient not affiliated with a social security scheme\n   * no CT scan available\n   * no lung function test available the year around CT scan","ALL","18 Years",{"count":99,"type":100},230,"ESTIMATED","OBSERVATIONAL","Emphysema linked to alpha-1-antitrypsin deficiency (DAAT): towards a better prediction of risks Emphysema caused by alpha-1-antitrypsin deficiency (DAAT) is a rare genetic disorder that can lead to serious complications, such as the need for a lung transplant or death, affecting up to 15% of patients. The only specific treatment available is a weekly infusion of alpha-1-antitrypsin (IV-AAT), an expensive and burdensome therapy.\n\nCurrently, there is no reliable model to predict the course of the disease in these patients. Our study, conducted in several French hospitals, aims to develop a prediction tool combining clinical, biological, functional data and advanced medical image analysis (lung CT). This model will make it possible to identify the most at-risk patients, in order to better adapt their care, anticipate transplant needs and avoid unnecessary treatments for low-risk patients.\n\nUltimately, this approach could also improve access to care for patients who need it most, while optimizing health system resources.",[104,105,106,107,108,109],"Alpha-1-antitrypsin Deficiency","Emphysema","Artificial Intelligence (AI)","Predictive Learning Models","Mortality Prediction","Lung Transplantation","2026-07-15",{"date":112,"type":113},"2026-07-20","ACTUAL",{"date":115,"type":113},"2026-02-16",{"date":117,"type":100},"2031-03-16",{"name":5,"class":6},4]